Huitian is the only plasma-based biopharmaceutical manufacturer in Shaanxi Province, which has a population of 37 million. Shaanxi Province historically has had a high collection volume with approximately ten plasma collection stations in operation, collecting approximately 300 tons of plasma supply each year. Huitian currently owns three out of the four plasma collection stations in Shaanxi Province that have passed government standards. Huitian produces approximately 80 tons of plasma-based products per year and has 200 tons of annual production capacity. Management believes that Huitian currently has approximately 1.2% of the market share in China, compared to China Biologic's estimated 6.1%, and that Huitian's plasma supply in Shaanxi Province has strong long-term growth potential. The top 6 largest plasma-based biopharmaceutical companies in China have a total market share of approximately 50%.
Huitian is also one of only 32 government approved plasma-based product producers in China, and it is in compliance with China's Good Manufacturing Practices standards. It is approved by the PRC's State Food and Drug Administration to produce four types of plasma-based products including Human Albumin, Human Immunoglobulin, Human Immunoglobulin for Intravenous Injection, and Human Hepatitis B Immunoglobulin.
China Biologic funded Taibang's acquisition of the 35% interest in Huitian
with internally generated fund from Taibang. Taibang's 17% minority
shareholder, the Shandong Institute of Biological Products, did not contribute
any amounts toward the Equity Tran
|SOURCE China Biologic Products, Inc.|
Copyright©2009 PR Newswire.
All rights reserved